TL;DR

End-of-life distress has some of the most statistically robust findings in all of psychedelic science: two 2016 randomized trials found large, durable reductions in depression, anxiety, and existential dread in patients with life-threatening cancer. But those effects came from single supervised full doses, not microdosing. This page exists because the evidence is strong and the distinction is one people genuinely need drawn: it is strong evidence for a full-dose, supported experience, and not a microdosing finding at all.

Why this matters

The end-of-life trials are among the reasons the modern psychedelic research era exists, and they are frequently cited — sometimes loosely — as evidence that psilocybin “works” in ways that get extended to microdosing. It does not extend that way. This page records what the trials actually showed and draws the line clearly. A shorter version appears in the 90-second summary on iMicrodosing.net.

A single dose, a durable shift

In 2016, two randomized controlled trials tested psilocybin for psychological distress in people with life-threatening cancer. At Johns Hopkins, 51 patients received a high dose (around 22–30 mg/70 kg) versus a placebo-like low dose in a crossover design, with substantial and sustained decreases in depression and anxiety that persisted at six-month follow-up. [1] Clinical trial Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) doi:10.1177/0269881116675513 The companion NYU trial in 29 patients found rapid and durable reductions in anxiety and depression, along with improvements in quality of life and spiritual wellbeing, after a single psilocybin session. [2] Clinical trial Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL (2016) doi:10.1177/0269881116675512 Critically, the dose was only one component of the intervention: the therapeutic structure included preparation, supervision during the session, and integration support afterward, delivered in what was effectively a palliative-care research context for cancer-related distress and existential anxiety. These are large effects from one carefully supported, full-dose experience — the defining feature of the evidence, and the reason it cannot be read as a microdosing result.

Key concepts
Single full dose, not a routine

The trials gave one high dose in a prepared, supervised setting with psychological support. Microdosing is repeated sub-perceptual self-administration. These are different interventions with different evidence. [1] Clinical trial Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) doi:10.1177/0269881116675513

Existential distress as the target

The outcome was distress specific to facing death — depression, anxiety, demoralisation, hopelessness — not general mood enhancement. The effect was measured in a defined clinical population. [2] Clinical trial Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL (2016) doi:10.1177/0269881116675512

Why it sits in this cluster at all

It is included because it is foundational and because the full-dose-vs-microdose distinction is most starkly illustrated here: the strongest evidence in the cluster is also the least applicable to microdosing. [3] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field Polito V, Liknaitzky P (2022) doi:10.1016/j.neubiorev.2022.104706

What this does not show

For all their strength, the end-of-life trials say nothing directly about microdosing. There is no body of microdose-specific end-of-life research, and the mechanism that plausibly drives the full-dose effect — an intense subjective or mystical-type experience, often involving a shift in meaning-making about mortality — is by definition absent at sub-perceptual doses. The field’s reviewers are explicit that full-dose and low-dose psychedelics are different research questions, and end-of-life distress is the clearest case where the evidence lives entirely on the full-dose side. [3] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field Polito V, Liknaitzky P (2022) doi:10.1016/j.neubiorev.2022.104706 Extending these results to microdosing is not a cautious inference; it is a category error.

Three things to keep straight

First, the effect is large and durable — this is not a weak or contested finding. Second, it came from a single full dose with psychological support, not a daily microdose. Third, there is no microdose-specific end-of-life evidence to stand in its place, and the likely mechanism does not operate at sub-perceptual doses. The result is strong, real, and about something other than microdosing.

Where end-of-life distress sits among the use cases

End-of-life distress sits in the strong tier on evidence quality, with an asterisk that matters more than the tier: the strength is full-dose strength. Among the twelve use cases, it is the cleanest example of why the cluster is organised by evidence quality with the dose distinction attached — a condition can have some of the best evidence in the field and still be, for microdosing purposes, a cautionary boundary rather than a supporting case. [3] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field Polito V, Liknaitzky P (2022) doi:10.1016/j.neubiorev.2022.104706 It shares this full-dose-versus-microdose boundary with depression and addiction, and the distinction itself is laid out in the cluster overview.

Is the end-of-life evidence about microdosing?

No. The landmark trials used single full doses of psilocybin in supervised sessions, not sub-perceptual microdosing. [1] Clinical trial Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) doi:10.1177/0269881116675513 They are strong evidence for a full-dose, supported experience — a different intervention. [2] Clinical trial Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL (2016) doi:10.1177/0269881116675512

How strong is the end-of-life evidence?

It is among the most statistically robust findings in psychedelic science: two 2016 randomized trials reported large, durable reductions in depression, anxiety, and existential distress after a single full dose. [1] Clinical trial Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA (2016) doi:10.1177/0269881116675513 The strength is real — and it is about full doses. [2] Clinical trial Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL (2016) doi:10.1177/0269881116675512

Why include it in a microdosing resource at all?

Because it is foundational to the field and the distinction needs drawing clearly. People encounter these trials and assume the results apply to microdosing; they do not transfer directly, and saying so plainly is the point of this page. [3] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field Polito V, Liknaitzky P (2022) doi:10.1016/j.neubiorev.2022.104706

In summary

End-of-life distress is the use case with some of the strongest evidence in psychedelic medicine and the least relevance to microdosing — a pairing that is only paradoxical if the dose distinction is dropped. The 2016 Johns Hopkins and NYU trials showed large, durable relief of existential distress from a single supervised full dose, and that finding is foundational. It is also, precisely, a full-dose finding: there is no microdose-specific evidence here, and the mechanism that likely drives the effect does not exist at sub-perceptual doses. The accurate reading is to hold the evidence in high regard and decline to stretch it.